Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Biotech rocket ride
La Jolla Pharmaceutical stock soars 76.75 percent
Stock of biotech La Jolla Pharmaceutical today (February 27) soared a rollicking 76.75 percent to $35.12. The company got excellent results in tests for a treatment for catecholamine-resistant hypotension, a life-threatening condition featuring inadequate blood flow to vital organs.
La Jolla's LJPC-501 worked for 70 percent of patients. Only 23 percent of patients given a placebo responded favorably. However, as Motley Fool pointed out, the treatment did not extend life spans of patients by a significant margin.
This company had worked two decades to develop a drug for lupus. In 2009 it failed in tests. Since that was the only drug in its pipeline, the company considered liquidation, arguing that its lupus drug was all it had. The stock plummeted to as low as 7 cents and the value of the company was said to be less than half that. But the company shifted its focus and scrapped on. Today's results and stock market rocket shot seems to validate management's approach.
Warning: Roller-coaster rides are common in biotech stocks. Most are only for investors who can stomach extreme volatility.
Here's something you might be interested in.
Biotech rocket ride
La Jolla Pharmaceutical stock soars 76.75 percent
Biotech rocket ride
La Jolla Pharmaceutical stock soars 76.75 percent
Stock of biotech La Jolla Pharmaceutical today (February 27) soared a rollicking 76.75 percent to $35.12. The company got excellent results in tests for a treatment for catecholamine-resistant hypotension, a life-threatening condition featuring inadequate blood flow to vital organs.
La Jolla's LJPC-501 worked for 70 percent of patients. Only 23 percent of patients given a placebo responded favorably. However, as Motley Fool pointed out, the treatment did not extend life spans of patients by a significant margin.
This company had worked two decades to develop a drug for lupus. In 2009 it failed in tests. Since that was the only drug in its pipeline, the company considered liquidation, arguing that its lupus drug was all it had. The stock plummeted to as low as 7 cents and the value of the company was said to be less than half that. But the company shifted its focus and scrapped on. Today's results and stock market rocket shot seems to validate management's approach.
Warning: Roller-coaster rides are common in biotech stocks. Most are only for investors who can stomach extreme volatility.
Comments